Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised

Nuvectis Pharma, Inc.

Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.
Net proceeds to fund development of NXP800 (Phase 1b ARID1a-mutated ovarian cancer) and NXP900 (Phase 1a SRC kinase inhibitor).
Lucid Capital Markets sole book runner; offering closed February 6, 2025, after option exercise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.